Tredje AP fonden Has $1.65 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Tredje AP fonden reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 50.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,337 shares of the life sciences company’s stock after selling 12,336 shares during the period. Tredje AP fonden’s holdings in Illumina were worth $1,649,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. WCM Investment Management LLC boosted its position in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after buying an additional 27,618 shares in the last quarter. Geode Capital Management LLC boosted its position in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after buying an additional 48,018 shares in the last quarter. Primecap Management Co. CA boosted its position in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after buying an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 1.8 %

Shares of NASDAQ:ILMN opened at $85.60 on Friday. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market capitalization of $13.56 billion, a PE ratio of -11.15, a PEG ratio of 1.60 and a beta of 1.17. The company has a 50 day moving average price of $113.52 and a two-hundred day moving average price of $129.88.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ILMN shares. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Piper Sandler boosted their price target on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Citigroup reduced their price target on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and reduced their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Barclays reiterated an “underweight” rating on shares of Illumina in a research report on Tuesday. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.